Product Name
GRHPR, siRNA
Full Product Name
GRHPR siRNA (Human)
Product Synonym Names
GLXR; Glyoxylate reductase/hydroxypyruvate reductase
Product Gene Name
GRHPR sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9UBQ7
Specificity
GRHPR siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human GRHPR gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of GRHPR sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
GRHPR sirna
siRNA to inhibit GRHPR expression using RNA interference
Applications Tested/Suitable for GRHPR sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for GRHPR. It may not necessarily be applicable to this product.
NCBI Accession #
NP_036335.1
[Other Products]
NCBI GenBank Nucleotide #
NM_012203.1
[Other Products]
UniProt Primary Accession #
Q9UBQ7
[Other Products]
UniProt Secondary Accession #
Q5T945; Q9H3E9; Q9H636; Q9UKX1[Other Products]
UniProt Related Accession #
Q9UBQ7[Other Products]
Molecular Weight
27,843 Da
NCBI Official Full Name
glyoxylate reductase/hydroxypyruvate reductase
NCBI Official Synonym Full Names
glyoxylate reductase/hydroxypyruvate reductase
NCBI Official Symbol
GRHPR [Similar Products]
NCBI Official Synonym Symbols
PH2; GLXR; GLYD
[Similar Products]
NCBI Protein Information
glyoxylate reductase/hydroxypyruvate reductase
UniProt Protein Name
Glyoxylate reductase/hydroxypyruvate reductase
Protein Family
Glyoxylate reductase/hydroxypyruvate reductase
UniProt Gene Name
GRHPR [Similar Products]
UniProt Synonym Gene Names
GLXR [Similar Products]
UniProt Entry Name
GRHPR_HUMAN
NCBI Summary for GRHPR
This gene encodes an enzyme with hydroxypyruvate reductase, glyoxylate reductase, and D-glycerate dehydrogenase enzymatic activities. The enzyme has widespread tissue expression and has a role in metabolism. Type II hyperoxaluria is caused by mutations in this gene. [provided by RefSeq, Jul 2008]
UniProt Comments for GRHPR
GRHPR: Enzyme with hydroxy-pyruvate reductase, glyoxylate reductase and D-glycerate dehydrogenase enzymatic activities. Reduces hydroxypyruvate to D-glycerate, glyoxylate to glycolate oxidizes D-glycerate to hydroxypyruvate. Defects in GRHPR are the cause of hyperoxaluria primary type 2 (HP2); also known as primary hyperoxaluria type II (PH2). HP2 is a disorder where the main clinical manifestation is calcium oxalate nephrolithiasis though chronic as well as terminal renal insufficiency has been described. It is characterized by an elevated urinary excretion of oxalate and L- glycerate. Belongs to the D-isomer specific 2-hydroxyacid dehydrogenase family.
Protein type: Carbohydrate Metabolism - glyoxylate and dicarboxylate; EC 1.1.1.79; Oxidoreductase; Carbohydrate Metabolism - pyruvate; EC 1.1.1.81
Chromosomal Location of Human Ortholog: 9q12
Cellular Component: peroxisomal matrix; cytoplasm; cytosol
Molecular Function: glyoxylate reductase (NADP) activity; protein homodimerization activity; carboxylic acid binding; hydroxypyruvate reductase activity; NAD binding; glycerate dehydrogenase activity
Biological Process: dicarboxylic acid metabolic process; metabolic process; glyoxylate metabolic process; excretion; protein oligomerization
Disease: Hyperoxaluria, Primary, Type Ii
Research Articles on GRHPR
1. GRHPR was genotyped in Japanese patients with PH2 and all GRHPR mutations described to date were reviewed in terms of geographic and ethnic association
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
